Integra Lifesciences Holdings (IART)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$16.72+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Adjusted EPS of $2.40 to $2.50 in FY26: FY26 EPS guide $2.40-$2.50 vs $2.40 target.
Integra LifeSciences grows revenue about 3.5% yearly with stable profit margins. The company raised its 2026 EPS guidance to $2.40-$2.50 per share. It beat Q1 earnings by 35%, showing strong execution. The stock trades cheap at a PE of 7.4 versus peers at 36.5.
Revenue growth is slow and profit margins remain under pressure. The company is loss-making on free cash flow. Analyst revisions have been mostly down recently. The stock could stay undervalued if growth disappoints.
The market prices the stock about 59% below our fair value near $42. Analysts expect about 3.5% revenue growth. Our view aligns with this but sees upside if EPS guidance is met and execution continues.
Breaks if: EPS falls below $2.40 in FY26
Breaks if: Q2 revenue falls below $410 million
Breaks if: YoY revenue growth falls below 3.5% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady revenue growth and margin improvement. The current thesis state is intact, supported by management's reaffirmation of guidance and recent earnings beats.
The market appears to have priced in a justified valuation, with IART being seen as cheap compared to its peers. There is a slight expectations gap, indicating that the market may not fully reflect the potential for revenue growth and operational improvements.
Management is on track to achieve its revenue growth guidance of 0.8% to 3.3%. However, the adjusted EPS guidance shows mixed signals, and there are risks associated with the broader economic environment that could impact performance.
The thesis hinges on several factors, including the potential for management to meet or exceed guidance, the performance of sector bellwethers, and the impact of economic conditions on the healthcare sector. Any cuts to guidance or worsening economic indicators could negatively affect the outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The company has reiterated its revenue guidance range for 2026 to be between $1.662 billion and $1.702 billion.
Overall, IART's fundamentals suggest a stable outlook, but investors should remain aware of the elevated risks and sector dynamics. Not investment advice.